Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (1) | Back to Search
A Road-to-Market Analysis for Non-Small Cell Lung Cancer Products: Tyrosine Kinase Inhibitors as a case study
- In: Poster Presentation
- At: Stockholm (Sweden) (2017)
- Type: Poster
- Poster code: P-D-005-Monday
- By: DELGADO-CHARRO, M Begona (University of Bath, Pharmacy and Pharmacology, Bath, United Kingdom)
- Co-author(s): M Begona Delgado-Charro: Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
Enrico Tognana: European Medicines Agency, EMA, London, United Kingdom
Francesco Pignatti: European Medicines Agency, EMA, London, United Kingdom
Corinne De Vries: European Medicines Agency, EMA, London, United Kingdom - Abstract:
Backgrounds
Pre- and post- submission factors influence the Road-to-Market for medicinal products.Aims
This work analysed the Road-to-Market for 10 NSCLC-TKIs products for which an MAA had been submitted.Methods
The choice was based on the clinical relevance and potential identification of the most significant factors in the Road-to-Market for
.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 28 September 2023